GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SpringWorks Therapeutics Inc (NAS:SWTX) » Definitions » Float Percentage Of Total Shares Outstanding

SpringWorks Therapeutics (SpringWorks Therapeutics) Float Percentage Of Total Shares Outstanding : 82.57% (As of May. 24, 2024)


View and export this data going back to 2019. Start your Free Trial

What is SpringWorks Therapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, SpringWorks Therapeutics's float shares is 61.18 Mil. SpringWorks Therapeutics's total shares outstanding is 74.09 Mil. SpringWorks Therapeutics's float percentage of total shares outstanding is 82.57%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, SpringWorks Therapeutics's Insider Ownership is 2.80%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, SpringWorks Therapeutics's Institutional Ownership is 63.68%.


SpringWorks Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

SpringWorks Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=61.18/74.09
=82.57%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SpringWorks Therapeutics (SpringWorks Therapeutics) Business Description

Industry
Traded in Other Exchanges
N/A
Address
100 Washington Boulevard, Stamford, CT, USA, 06902
SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.
Executives
Tai-an Lin officer: Chief Scientific Officer C/O SPRINGWORKS THERAPEUTICS, INC., 100 WASHINGTON BOULEVARD, STAMFORD CT 06902
Julie Hambleton director C/O FIVE PRIME THERAPEUTICS, INC., TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Jeffrey Lawrence Schwartz director, 10 percent owner C/O BAIN CAPITAL LIFE SCIENCES, LP, 200 CLARENDON STRERET, BOSTON MA 02116
Daniel Pichl officer: Chief People Officer C/O SPRINGWORKS THERAPEUTICS, INC., 100 WASHINGTON BLVD., STAMFORD CT 06902
James Cassidy officer: Chief Medical Officer 368 NOD HILL ROAD, WILTON CT 06897
Orbimed Advisors Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Carlos Alban director 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Saqib Islam director, officer: Chief Executive Officer ALEXION PHARMACEUTICALS, 352 KNOTTER DRIVE, CHESHIRE CT 06410
L. Mary Smith officer: See Remarks C/O SPRINGWORKS THERAPEUTICS, INC., 100 WASHINGTON BLVD., STAMFORD CT 06902
Bain Capital Life Sciences Investors, Llc 10 percent owner 200 CLARENDON STREET, BOSTON MA 02116
Michael F. Burgess officer: Head of Research & Development C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMRIDGE MA 02142
Stephen P Squinto director, 10 percent owner C/O ALEXION PHARMACEUTICALS INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Bhavesh Ashar officer: Chief Commercial Officer C/O SPRINGWORKS THERAPEUTICS, 100 WASHINGTON BLVD, STAMFORD CT 05902
Orbimed Capital Gp Vi Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Badreddin Edris officer: Chief Business Officer C/O SPRINGWORKS THERAPEUTICS, INC., 100 WASHINGTON BLVD., STAMFORD CT 06902

SpringWorks Therapeutics (SpringWorks Therapeutics) Headlines

From GuruFocus

SpringWorks Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

By Stock market mentor Stock market mentor 01-03-2023